Neurological Disease

Z164597606 is a selective BChE inhibitor (IC₅₀: 1.3 and 1.7 μM for eqBChE and hBChE). Z164597606 forms a π-π stacking interaction with the amino acid Trp82 of hBChE. Z164597606 can be used for the research of Alzheimer’s disease (AD).

(S)-2-Benzylpyrrolidine (Compound s1) serves as a METH hapten scaffold. (S)-2-Benzylpyrrolidine attenuates Methamphetamine-induced hyperlocomotion, hyperthermia and respiratory depression. (S)-2-Benzylpyrrolidine alleviates sedative agent-induced respiratory depression.

BTB 06061 is a TRPM7 inhibitor and can be used for study of ischemic disease.

MR2938 is a potent AChE inhibitor, with an IC₅₀ of 5.04 μM. MR2938 also suppresses NO production obviously (IC₅₀ = 3.29 μM). MR2938 suppresses the neuroinflammation through blocking MAPK/JNK and NF-κB signaling pathways. MR2938 can be used for Alzheimer’s disease (AD) research.

LY3154885 is an orally active dopamine D1 receptor positive allosteric modulator (PAM). LY3154885 has an improved agent-agent interactions (DDI) risk profile.

5-HT2C-agonist-14 is a 5-HT2C receptor agonist with an EC₅₀ of 2.9 μM against human receptors. It also acts as a voltage-gated sodium channel inhibitor with blood-brain barrier permeable. 5-HT2C-agonist-14 elevates seizure threshold, suppresses seizure progression and alleviates pain-related behaviors. It can be used in the research of epilepsy and pain-related diseases.

TRPA1-IN-5 is a TRPA1 inhibitor with inhibitory activity against TRPA1. TRPA1-IN-5 has pharmacokinetic and pharmacodynamic activities.

BU09059 is a potent and selective Kappa-opioid receptor antagonist with a pA₂ of 8.62. BU09059 has nanomolar affinity for the κ-receptor, with 15-fold and 616-fold selectivity over μ- and δ-receptors, respectively. BU09059 significantly blocks U50488 (HY-15997B)-induced antinociception.

R 29676 is a neuroleptic agent and inhibits sodium-dependent GABA binding (GABA uptake).

20(R)-Notoginsenoside R2 is an isolated notoginsenoside from Panax notoginseng.

Pueraria tuberosa extract is rich in puerarin, daidzein, genistein, and flavonoids, which give it antioxidant, anti-inflammatory, cardioprotective, and neuroprotective effects.

Neuroprotective agent 2 (Compd 28) is a potent neuroprotective agent which has a protective effect in both salsolinol and glutamate-induced neurodegeneration models. Neuroprotective agent 2 reduces oxidative stress and caspase-3/7 activity in the glutamate model.

TBC-4746 is a α4β1/α4β7 integrin antagonist. TBC-4746 can be used in the research of asthma and multiple sclerosis.

HDAC-IN-62 (Compound 5) a HDAC inhibitor, with IC₅₀s of 0.78, 1.0, 1.2? μM for HDAC6/8/11 respectively. HDAC-IN-62 inhibits-induced microglial activation by the initiation of autophagy, and inhibits nitric oxide production. HDAC-IN-62 has anti-inflammatory and anti-depressant effects. HDAC-IN-62 inhibits microglial activation in mouse brain.

NM600 is an alkylphosphocholine mimetic RPT agent. NM600 demonstrates an antitumor activity against a second GD2+ neuroblastoma xenograft model with SY5Y cells. NM600 can enhance suboptimal CAR T cell efficacy against solid tumors. NM600 can be studied in research for neuroblastoma.

Ordopidine is a dopamine D2 receptor antagonist. Ordopidine can inhibit hyperactivity caused by psychostimulants. Ordopidine can be used in neurological research.

SL-164 is a quinazolinone. SL-164 has sedative properties.

VU6007496 is a highly selective and CNS penetrant M1 positive allosteric modulator (PAM). VU6007496 shows excellent pharmacokinetics (PK).

Bulbocapnine hydrochloride, an aporphine alkaloid, is a dopamine receptor inhibitor. Bulbocapnine hydrochloride inhibits dopamine synthesis. Bulbocapnine hydrochloride also has neuroleptic-like, anticonvulsant and antinociceptive effects.

7-Hydroxyquetiapine (ICI 214227) is the major active metabolite of antipsychotic medicine Quetiapine^[1].